Medical Marijuana and ALS: Neuroprotection, Spasticity, and Quality of Life Research

Amyotrophic lateral sclerosis (ALS) is one of the cruelest diagnoses in medicine. Motor neurons degenerate progressively, stripping away the ability to move, speak, swallow, and eventually breathe — while cognition typically remains intact. Median survival after diagnosis is 2 to 5 years. The FDA-approved treatments (riluzole and edaravone) extend survival by months at best, and neither reverses the disease.

Against that backdrop, the interest in medical marijuana among ALS patients isn't surprising. It's pragmatic. When your disease has no cure and limited treatment options, you pay attention to anything that might slow progression, relieve symptoms, or improve the quality of whatever time remains.

The research on medical marijuana and ALS is limited but mechanistically compelling. Here's what exists.

The Endocannabinoid System in Motor Neuron Disease

ALS involves the degeneration of both upper and lower motor neurons, leading to progressive weakness, spasticity, fasciculations, and eventually respiratory failure. The pathophysiology includes excitotoxicity (excessive glutamate signaling), oxidative stress, neuroinflammation, and mitochondrial dysfunction.

The endocannabinoid system intersects with each of these mechanisms:

• CB1 receptors are densely expressed on motor neurons in the spinal cord and brainstem. They modulate glutamate release and can reduce excitotoxic damage.
• CB2 receptors are expressed on microglia — the immune cells of the central nervous system. When activated, they shift microglia toward anti-inflammatory phenotypes, potentially reducing the neuroinflammation that accelerates motor neuron death.
• Endocannabinoid tone appears to change as ALS progresses. A 2004 study by Witting et al. in Neuroscience Letters found elevated endocannabinoid levels (specifically anandamide and 2-AG) in the spinal cords of ALS mice, suggesting the ECS is upregulated as a compensatory neuroprotective response.

Preclinical Evidence: Animal Studies in ALS Models

The SOD1 transgenic mouse is the most widely used animal model of ALS. These mice carry a mutation in the superoxide dismutase 1 gene that causes progressive motor neuron degeneration similar to familial ALS in humans.

THC and Disease Progression

A landmark 2004 study by Raman et al. in Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders administered THC to SOD1 mice beginning at the onset of motor impairment. The results:

• THC-treated mice showed significantly delayed motor impairment compared to controls
• Survival was extended by approximately 5% — modest, but notable given that riluzole provides a similar magnitude of benefit in humans
• Motor neuron loss in the lumbar spinal cord was reduced in the THC group

Cannabinol (CBN) and Motor Neuron Survival

A 2005 study by Weydt et al. in the Journal of Neurochemistry tested cannabinol (CBN) — a less-studied cannabinoid — in the SOD1 model. CBN delayed disease onset by more than 2 weeks and significantly extended survival. The effect was attributed to CBN's antioxidant properties and its ability to reduce excitotoxicity without producing significant psychoactive effects.

WIN 55,212-2 (Synthetic Cannabinoid)

A 2006 study by Bilsland et al. in FASEB Journal used WIN 55,212-2, a synthetic cannabinoid agonist, in SOD1 mice. Treatment beginning after symptom onset:

• Slowed disease progression
• Reduced motor neuron loss by approximately 40%
• Delayed the onset of hindlimb weakness

Interestingly, genetic deletion of FAAH (the enzyme that degrades anandamide) in SOD1 mice also slowed disease progression — suggesting that boosting the body's own endocannabinoid levels may be neuroprotective in ALS.

CB2 Receptor and Neuroinflammation

A 2014 study by Moreno-Martet et al. in ACS Chemical Neuroscience demonstrated that selective CB2 receptor activation in SOD1 mice reduced reactive gliosis (the inflammatory activation of glial cells that damages surrounding neurons) and preserved motor function longer than in untreated animals.

Human Evidence: What We Have

Survey Data

A 2004 survey by Amtmann et al. in the American Journal of Hospice and Palliative Care found that ALS patients who used medical marijuana reported improvement in:

• Appetite loss (improvement reported by 73% of users)
• Depression (55%)
• Pain (60%)
• Spasticity (55%)
• Drooling/sialorrhea (38%)

A larger 2017 survey by Gelinas et al. in the Canadian Journal of Neurological Sciences found that approximately 10-15% of ALS patients in North America reported medical marijuana use, with the most common reasons being pain relief, spasticity reduction, and mood improvement.

The Nabiximols (Sativex) Trial

The most rigorous human trial to date was published in 2019 by Riva et al. in The Lancet Neurology. This was a randomized, double-blind, placebo-controlled trial of nabiximols (a 1:1 THC:CBD oromucosal spray) in 59 ALS patients with moderate to severe spasticity.

Results:

• Nabiximols produced a statistically significant reduction in spasticity compared to placebo, as measured by the Modified Ashworth Scale
• The treatment was well-tolerated, with dizziness and fatigue as the most common side effects
• No acceleration of disease progression was observed in the treatment group
• Quality of life measures showed trends toward improvement but did not reach statistical significance

This trial was small, but it remains the gold standard for medical marijuana in ALS and directly supports spasticity as a treatable symptom.

Cerebrospinal Fluid Studies

A 2020 study by Urbi et al. in BMC Neuroscience analyzed endocannabinoid levels in the cerebrospinal fluid of ALS patients and found altered 2-AG and anandamide concentrations compared to healthy controls — consistent with the animal data suggesting ECS dysregulation in ALS.

Symptom-by-Symptom Analysis

ALS produces a constellation of symptoms, several of which have biological rationale for cannabinoid treatment:

Spasticity

The strongest evidence exists here. Spasticity — the involuntary muscle tightness that causes pain, limits mobility, and interferes with sleep — affects the majority of ALS patients. The nabiximols trial directly demonstrated efficacy, and the mechanism is well-understood: CB1 activation reduces excitatory neurotransmission in spinal motor circuits.

Current first-line spasticity treatments (baclofen, tizanidine, dantrolene) all carry significant side effects including sedation, weakness, and hepatotoxicity. Medical marijuana may offer a complementary or alternative approach.

Pain

Pain in ALS is underappreciated. A 2019 systematic review by Chiò et al. in European Journal of Neurology found that 60-85% of ALS patients experience pain, including muscle cramps, joint pain from immobility, neuropathic pain, and spasticity-related pain. The analgesic properties of medical marijuana are well-established for chronic pain conditions generally, and survey data from ALS patients consistently reports pain relief as a primary benefit.

Appetite Loss and Weight Management

Weight loss in ALS accelerates disease progression — this is one of the clearest prognostic factors in the disease. THC's appetite-stimulating effects (mediated through CB1 receptors in the hypothalamus) could theoretically slow the catabolic decline that worsens outcomes.

A 2007 study by Heffernan et al. found that ALS patients treated with dronabinol (synthetic THC) showed trends toward weight stabilization, though the study was underpowered to reach statistical significance.

Sleep Disruption

Difficulty sleeping is nearly universal in ALS, driven by pain, spasticity, respiratory insufficiency, anxiety, and positioning difficulties. Medical marijuana's effects on sleep — particularly THC's sleep-onset effects and CBD's anxiolytic properties — align with the multifactorial nature of ALS-related insomnia.

Sialorrhea (Excess Saliva)

Drooling due to impaired swallowing is one of the most distressing symptoms for ALS patients. There's limited direct evidence for medical marijuana treating sialorrhea, though survey data suggests some patients experience benefit — potentially through THC's mild anticholinergic-like drying effect at certain doses.

Depression and Existential Distress

Living with a terminal progressive neurological disease produces understandable psychological distress. While the evidence for medical marijuana in depression is complex and dose-dependent, the anxiolytic effects of CBD and the mood-modulating properties of low-dose THC may offer some relief in a palliative context where quality of life is the primary treatment goal.

The Neuroprotection Question

The most scientifically interesting — and clinically unproven — aspect of medical marijuana in ALS is the neuroprotection hypothesis.

The preclinical data is consistent: cannabinoids reduce excitotoxicity, decrease neuroinflammation, scavenge free radicals, and protect motor neurons in animal models. But translating neuroprotection from mouse models to human disease is one of the most persistently disappointing endeavors in neurology. Dozens of compounds that protected motor neurons in SOD1 mice have failed in human trials.

The honest assessment: we do not have evidence that medical marijuana slows disease progression in human ALS. We have biological reasons to think it might, and animal data that supports the hypothesis, but no clinical trial has demonstrated disease-modifying effects.

What we do have is evidence that it can improve symptoms and quality of life — and in a disease with a 2-5 year median survival and limited treatment options, that matters enormously.

Practical Considerations for ALS Patients

Route of Administration

This deserves special attention in ALS because swallowing difficulty (dysphagia) is common and progressive. As the disease advances, oral administration becomes difficult or impossible. Options include:

• Sublingual/oromucosal sprays — bypasses swallowing, and nabiximols has direct trial evidence in ALS
• Vaporization — rapid onset, but respiratory compromise in ALS may limit this approach
• Transdermal — slower onset but avoids both oral and pulmonary routes
• Rectal — bioavailability is moderate but may be the most practical route in advanced disease

Smoking is contraindicated in ALS. The respiratory system is already compromised, and combustion byproducts would add unnecessary insult.

Drug Interactions

ALS patients are often taking riluzole, which is metabolized by CYP1A2. CBD is a CYP1A2 inhibitor, which could increase riluzole blood levels and potentially increase its hepatotoxic effects. This interaction needs to be monitored — liver function testing should be more frequent in patients using both.

Timing in Disease Course

There's no evidence-based answer to "when should I start?" The neuroprotection hypothesis would argue for early initiation, while a symptom-management approach would begin when symptoms warrant treatment. Most patients in clinical practice start medical marijuana for symptom management, and symptom burden tends to increase as the disease progresses.

The Policy Perspective

ALS is a qualifying condition for medical marijuana in all U.S. states that have medical marijuana programs, including Florida. This reflects a consensus — unusual in medical marijuana policy — that the risk-benefit calculus for terminally ill patients with limited treatment options clearly favors access.

The ALS Association has stated that it "understands the interest of people with ALS in medical marijuana" and supports further research. The Muscular Dystrophy Association has similarly called for expanded clinical trials.

Where Research Needs to Go

The ALS-medical marijuana field needs:

1. Larger randomized controlled trials — the nabiximols trial enrolled only 59 patients. Adequately powered trials with disease progression endpoints are essential.
2. Disease-modification studies — not just symptom management, but functional decline rate as a primary outcome
3. Biomarker studies — measuring neurofilament light chain (NfL) and other ALS biomarkers during medical marijuana treatment to assess potential neuroprotective effects
4. Route-of-administration comparisons — particularly relevant given the progressive dysphagia and respiratory compromise in ALS
5. Head-to-head trials against current spasticity and pain treatments

The Bottom Line

ALS patients deserve honest assessments, not false hope. Here's the honest assessment:

Medical marijuana has demonstrated efficacy for spasticity in ALS through a randomized controlled trial. It has reasonable evidence for pain, appetite stimulation, and sleep improvement based on survey data and broader chronic disease literature. It has compelling preclinical evidence for neuroprotection that has not yet been confirmed in human trials.

In the context of a uniformly fatal disease with minimal treatment options, the risk-benefit calculation for medical marijuana is more favorable than for almost any other condition. The goal is quality of life, and the available evidence suggests medical marijuana can contribute to that goal.

If you or a loved one is living with ALS and you want to discuss whether medical marijuana might help with symptom management, you can schedule an evaluation at [coral.clinic/start](https://coral.clinic/start). Dr. Kim will review your current treatment plan, discuss realistic expectations, and help you make an informed decision.